Thirty seven (37), initially classified as not hypertensive, received antihypertensive medication from their family doctor during follow-up and were subsequently excluded. Five (5) patients were lost in the follow-up. All remaining 356 patients underwent measures of office blood pressure (BP), 24-hour BP monitoring, echocardiography, urine and blood samples for albuminuria, diabetes and cholesterol as well as measurements of carotid-femoral PWV and pulse wave analysis. Primary hypertension was defined according to guidelines 1 : office BP above 140/90 mm Hg and/or 24-hour BP above 130/80 mm Hg. Patients in whom hypertension diagnosis was confirmed, received the usual care treatment: antihypertensive prescription and life style advices, consisting of moderate salt restriction, a low-calorie diet if overweight and advice for physical activity, aiming at 5 sessions/ week, with advised maximum heart rate during exercise adjusted to age. Patients whose hypertension diagnosis was not confirmed only received life style advices. After 1 year, all patients, even patients in whom the hypertension diagnosis had not been confirmed, were called back to be re-evaluated.
PROCEDURES
Office BP was measured in triplicate in sitting position with a 5-minute interval. The average of 3 readings was used. While lying down, additional BP measurements were performed and used for pulse wave analysis calibration.
Blood samples were obtained in the morning after an 8 hours fast and analyzed as explained elsewhere. 19, 20 Patients were diagnosed with moderately increased albuminuria when UAE rate was higher than 30 mg/g in men and women. 5 Regression of moderately increased albuminuria was defined when the urinary albumin to creatinine ratio changed class and additionally when the reduction was equal or superior to 50%.
Ambulatory BP monitoring
Twenty-four hour BP monitoring was performed with the Spacelabs 90207 recorder (Spacelabs) as explained elsewhere. 19 
Echocardiography
Echocardiography was performed using a SONOS 1000 (Hewlett Packard) following standard procedure explained elsewhere. 21 Left ventricular hypertrophy (LVH) was defined as left ventricular mass index greater than 115 g/m 2 in men and 95 g/m 2 in women. 1 
Pulse wave analysis
Pulse wave analysis was performed with the SphygmoCor CVMS device (version 8, AtCor Medical, Australia) from radial tonometry and calibrated with brachial pressure obtained just prior to the tonometry recording. Only recordings with a quality index over 80 were used in the study. All measures were done in duplicate and the average of 2 used for further analysis.
Pulse wave velocity
Carotid-femoral PWV was performed with the SphygmCor CVMS device. According to the European Arterial Stiffness Consensus, 22 the arterial distance was measured as 0.8 times the direct carotid to femoral distance. Only recordings with a SD below 10% were used. Elevated PWV was defined when PWV value was above 10 m/s as published by the ESH/ESC Guidelines. 1 
STATISTICS
Results are expressed as mean ± SD for continuous variables and as percentages for categorical variables. Comparison among groups was performed using the χ 2 test. Correlations between PWV and other variables were calculated using Pearson's method. BP is a major confounder of PWV. Indeed lower pressure within the artery leads to mechanically lower arterial stiffness even in the absence of any arterial wall remodeling. To evaluate the modifications of arterial stiffness independently of BP, PWV values were adjusted to mean arterial pressure (MAP) and MAP was calculated as DBP + 0.4 (SBP − DBP).
In order to test factors related to changes in PWV, we performed linear mixed effects-model multivariate analysis where the difference in BP-adjusted PWV (Δ-PWV) between baseline and follow-up was the dependent variable. Adjusting for gender, age, and baseline PWV, the 3 different measures of BP (office brachial BP, central BP, and ambulatory BP monitoring) were entered as independent variables in the model and corrected for known factors of cardiovascular risk as cholesterol, smoking, diabetes, and body mass index.
RESULTS

General characteristics of patients
Characteristics at entry of the 356 patients (177 male/179 female) are presented in Table 1 . The mean time interval between the 2 measurements was 1.21 years (SD ± 0.39) with no difference between treatment and control group (1.22 vs. 1.21 years, P = 0.69). Hypertension diagnosis was confirmed in 231 patients (64.9%). At entry, they were all treatment-naïve regarding hypertension, with no diabetes or previous cardiovascular event. Seven (5.6%) in the control group and 31 (13.5%) in the treatment group were on statins. In agreement with the reference range paper, 23 PWV was strongly correlated with age (R 2 = 0.582; P < 0.0001) and MAP (PWV = 0.045 * MAP + 3.73, R 2 = 0.277, P < 0.0001). Mean MAP in the whole group at baseline was 104 mm Hg. We subsequently linearly adjusted PWV to MAP (adjusted PWV = PWV -0.045 * (MAP − 104)) and all following results are presented with MAP-adjusted PWV. MAPadjusted PWV can also be interpreted as predicted PWV for a MAP of 104 mm Hg.
We divided the cohort according to the hypertension diagnosis and Table 2 presents their data at baseline and at 1-year follow-up. Figures 1 and 2 present TOD prevalence at baseline and its changes during the follow-up.
Control group
Patients in the control group were younger, more often female, had a slightly lower body mass index and had lower office BP, 24-hour BP, and central SBP ( Table 2) . They also had lower prevalence of TOD ( Figure 2 ): lower left ventricular mass index (P = 0.0001), lower prevalence of moderately increased albuminuria (P = 0.0001), lower UAE (P = 0.014), lower adjusted PWV (8.0 vs. 8.6 m/sec; P = 0.001), and lower prevalence of elevated PWV (P = 0.001).
After 1 year of follow-up, a total of 11 (8.8%) patients were on statins. Body mass index significant decreased (P = 0.014), UAE levels were slightly lower (P = 0.052), and HbA1c slightly increased (P < 0.001). There were no significant changes in measures of TOD in the control group ( Figure 2 ). Only MAP-adjusted PWV in this group tended to be slightly lower at follow-up (P = 0.017). Figure 1 presents the TOD prevalence in the whole group. Approximately half (47%) of the newly diagnosed hypertensive patients presented at least 1 TOD with considerable overlap between TOD. Hypertensive patients had a higher unadjusted PWV and this difference remained after MAP adjustment ( Table 2) . After 1 year of treatment, BP was well controlled in the hypertensive group (Table 2 ). The reduction of office BP was accompanied by a reduction of 24-hour and central BP of the same magnitude (Table 2) . We also observed a decrease of PWV (P < 0.0001), MAP-adjusted PWV (P < 0.001), and other TOD. HbA1c increased similarly in both groups while a small reduction in total cholesterol and low-density lipoprotein was observed (P = 0.001, Table 2 ). This could be explained by the fact that a third (n = 76) of patients in the treatment group were also receiving statins.
Treatment group
Expressed as percentages (Figure 2 ), the prevalence of elevated stiffness (unadjusted PWV > 10 m/s) was reduced from 19.9% at baseline to 12.1% at follow-up which paralleled the decrease of the prevalence of LVH (26.0-13.0%) and of elevated UAE (14.2-6.3%). Figure 3 shows PWV and adjusted PWV in control and treatment groups at baseline and at 1-year follow-up. PWV reduction was similar in both groups (Δ-PWV adjusted −0.27 vs. −0.20 m/sec; P = 0.553) in control and treatment group, respectively, with similar achieved BP levels at 1 year. Figure 4 shows the association of changes in adjusted PWV with changes in BP (results of unadjusted PWV were similar to those of adjusted PWV, data not shown). Additional variables related to changes in adjusted PWV were age, gender, and PWV at entry. As shown by multivariate linear analysis, patients with the higher stiffness at entry and with greater reduction of central DBP improved their PWV the most.
Association between changes in BP and adjusted PWV
Effect of antihypertensive class
Due to our mode of recruitment, patients were mostly uncomplicated stage 1 hypertensive. Monotherapy was sufficient to control BP in most patients (75%) while 21% were on bitherapy, 3% on tritherapy, and 1% received 4 different antihypertensive drugs.
Inhibitors of the renin-angiotensin-aldosterone system (n =172-71%).
Patients treated with a renin-angiotensinaldosterone system inhibitor (165 angiotensin II receptor blockers and 7 angiotensin-converting enzyme inhibitors) had the same BP at entry and improved their BP to the same level as other treated patients. Heart rate did not change. Adjusted PWV was improved but no more than for other classes.
Beta-blockers (n =44-19%).
Patients who received betablockers (Nebivolol n = 41 or Carvedilol n = 3) had higher SBP at entry (data not shown) and slightly higher heart rate. They also had higher MAP-adjusted PWV (9.3 vs. 8.4 m/s, P = 0.005). After 1 year of treatment, brachial and central BP fell to the same level as patients treated with other classes (data not shown) but heart rate was significantly lower. The reduction of MAP-adjusted PWV was greater than in other antihypertensive classes (0.8 vs. 0.2 m/s, P = 0.01).
Calcium channel blockers (n = 39-17%).
Patients treated with calcium channel blockers were no different from other Values are expressed as mean ± SD. Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; LDL, low-density lipoprotein; LVM, left ventricular mass; PWV, pulse wave velocity; SBP, systolic blood pressure.
regarding their BP, heart rate, or PWV at entry, except for office DBP (91 vs. 85, P = 0.002). After 1 year of treatment, their BP and PWV fell to the same extent than in other treated patients despite a small increase in heart rate (71 to 76 bpm, P = 0.045).
Diuretics (n = 40-17%).
In all but 2 patients, diuretics were used as the second drug. These patients started with higher BP at entry explaining why a bitherapy was necessary. They also had higher adjusted PWV at entry (9.1 vs. 8.5 m/s, P = 0.05), but after 1 year, their PWV was at the same level as other treated patients indicating a tendency toward a higher reduction in PWV (0.6 vs. 0.2 m/s, P = 0.089).
DISCUSSION
The present study looked at the determinants of changes of arterial stiffness after 1 year of standard routine management in a cohort of treatment-naïve mild hypertensive Spanish subjects, compared to a cohort of prehypertensive patients in whom hypertension diagnosis was not confirmed. As far as we are aware, this is the first study in standard clinical settings. There are 3 main findings in the present study. Firstly, elevated arterial stiffness defined as PWV >10 m/s is present in a fifth (20%) of the mild treatment-naïve hypertensive subjects. Secondly, early and intensive antihypertensive treatment as conducted in standard routine clinical practice achieves significant reductions of PWV, and decreases arterial stiffness prevalence after 1 year of follow-up by approximately 40 %. And thirdly, the main factor associated with a PWV decrease is effective BP reduction independently of treatment class.
In mid and lower risk groups like our cohort, PWV has been found to be particularly useful to reclassify patients' cardiovascular risk. 24, 25 In a general untreated Danish population, elevated PWV was reported the most prevalent TOD 24 and with higher reclassification power than LVH or moderately increased albuminuria. 26 We also previously presented data on the prevalence of TOD in a similar never-treated hypertensive population. 19 However, these Data presented as average ± SD, adjusted PWV means pulse wave velocity adjusted to mean blood pressure. Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVM, left ventricular mass; PWV, pulse wave velocity; SBP, systolic blood pressure.
articles, published in 2010, did not use the latest guidelines 1 regarding the definition of arterial distance used for PWV (0.8 × direct carotid-femoral distance), 22 of elevated PWV (threshold is now 10 m/s), of LVH (115 g/m 2 for men and 95 g/m 2 for women), or of presence of moderately increased albuminuria (threshold of 30 mg/g). 1 The clinical impact of these new definitions is high: with today definitions, 47% of our cohort has one or more TOD. Arterial stiffness is a relatively newly recognized TOD and still little used in clinical practice, 1,27 maybe due to the lack of known therapeutic procedures to improve it. 6 Left ventricular mass suffers similar paucity in treatment strategies to improve; however, it is used very frequently. Our study shows that arterial damage is as frequent as LVH in newly diagnosed patients (with only 50% overlap) and most importantly, it is possible to have a positive impact on arterial stiffness with early effective BP reduction.
Our present data confirm our previous results regarding the reduction of LVH and moderately increased albuminuria. 5, 21, 28 However as far as we know, this is the first observational longitudinal study looking at the prevalence and changes of arterial stiffness in mild hypertension under routine clinical management. Most published studies were controlled interventional protocols, looking at the effect of angiotensin-converting enzyme inhibitors 7, 8, [13] [14] [15] or angiotensin II receptor blockers 11, 12, 16 on the reduction of arterial stiffness. Ong et al. 9 pooled data from several of these randomized trials with follow-up up to 6 months. Other studies were longitudinal studies in treated hypertensives. 17, 18, 29 Benetos et al. 17 looked at the determinants of the progression of PWV over 6 years in normotensive and treated hypertensives, but treatment-naïve patients at entry were excluded from the analysis. Ait-Outfella et al. 18 showed an improvement of PWV in already treated patients with essential hypertension and on a follow-up of more than 5 years. Taken together, these last 2 studies suggest that improvement of PWV is possible in treated hypertensive subjects. 10 Our study was performed in treatment-naïve mild hypertensive subjects and showed that reduction of MAP-adjusted PWV was visible after as little as 1 year of BP control. We used baseline PWV-MAP relationship to adjust PWV to a fixed MAP value in order to account for the confounding mechanical effect of BP. We observed no significant difference in the decrease of MAP-adjusted PWV values after 1 year of follow-up in both groups indicating that the reduction in arterial stiffness is driven by the mechanical effect of MAP reduction.
The clinical implications of this observation are large, for keeping BP under control in recently diagnosed hypertensive patients might prevent further arterial stiffening 30 but even 1 year of optimal treatment and achieved targets, normalization of PWV was not obtained.
The role of baseline PWV deserves further discussion. Higher baseline values of adjusted PWV were associated with a higher decrease of PWV at follow up in the treatment group. Similarly, higher values of left ventricular mass or urinary excretion at baseline have been shown to be associated with a greater regression after treatment. 20, 28, 31 This underlines the fact that, as with other TODs, pretreatment values are essential determinants of regression, according to Wilder's principle, as pointed out by Messerli et al. 32 Future studies will show if regression of elevated PWV is as important as or even more important than LVH and moderately increased albuminuria as intermediate markers of cardiovascular diseases.
In interventional trials, renin-angiotensin-aldosterone system inhibitors have been found to be effective to reduce PWV, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] maybe by inducing specific remodeling of the arterial wall. 10, 33 However, little data on other classes are available and do not preclude positive effects of other classes on adjusted PWV. Among trials with a follow-up longer than 4 weeks, Ong observed that all classes were as effective to reduce PWV, and this beyond BP. 9 Our study is not an interventional trial and was not designed to study the effect of the various antihypertensive drug classes nor of statins. We nonetheless observed that after 1 year of real world management, all antihypertensive classes reduced PWV to the same extent, with the exception of "vasodilator" beta-blockers which presented a larger reduction in MAP-adjusted PWV. This result could be surprising at first, especially when compared to the CAFÉ/ ASCOTT 34 trial. However, this study used Atenolol while our patients were on Nebivolol, a so-called "vasodilator" beta-blocker with specific effects on central hemodynamics. 35 We observed that central pressure in nebivolol patients was reduced to the same extent as in other groups (17.4 vs.
16.7 mm Hg, P = 0.82). Probably due to the vasodilating effect of Nebivolol, PWV reduction was secondary to: 1-higher pretreatment values, 2-BP reduction, 3-probably some remodeling as for the other antihypertensive classes, and 4-to further reduction caused by decrease in heart rate.
LIMITATIONS OF THE STUDY
Several important limitations of our study must be considered. Our study is not an interventional trial but an observational study describing the effect of standard routine management. Besides, lack of randomization implies that the study design does not allow to find differences between drug classes. Patients's compliance was not addressed, differences between drugs may be due to varying adherence to treatment. In the treatment group, in order to tackle their whole TOD profile, more patients were on statins medication with a relatively small but statistically significant reduction on total cholesterol and low-density lipoprotein. We cannot exclude that part of the PWV reduction is driven by improvement of the lipid profile. Definition of elevated stiffness remains a disputable issue. It is possible to compare arterial stiffness according to age reference values, but the threshold of 10 m/s, as recommended by the European Guidelines, seemed to us to be more suitable in routine clinical practice: as for LVH, moderately increased albuminuria and even elevated BP itself, simple clear-cut thresholds are used in routine and have demonstrated their added value. Changes in lifestyle behavior were not recorded. The same advices were given to both group but we cannot estimate possible differences between groups in following these lifestyle advices. Our adjustment is based on a linear relationship between PWV and pressure at the pressure range observed. Finally, our treatment-naïve patients must be located at the very beginning of the cardiovascular continuum, we can only speculate on the translation of our results to long-standing hypertension, where decoupling of stiffness and BP might be feasible.
CONCLUSION
Overall, we found that it is possible in routine clinical practice to reduce PWV in the range of, but not beyond BP lowering after as little as 1 year of antihypertensive treatment in newly diagnosed stage 1 hypertensive patients. Patients with the highest stiffness value and with the largest reduction of BP achieve the best arterial destiffening, whatever antihypertensive class was used. Similarly to other TODs, arterial stiffness is capable of regressing when adequate treatment is settled, confirming that rapid tight control of BP is important, especially in relatively low-risk hypertensive patients. This represents further evidence that arterial stiffness should be measured in mild hypertensive patients and gives further motivation for tight BP control. DISCLOSURE S.M. works as a freelance specialist on pulse wave analysis and receives revenues from several medical devices companies including AtCor Medical whose device has been used in this study. The other authors declared no conflict of interest.
